CO6290651A2 - Inhibidores de cinesina como producto terapeuticos para el cancer - Google Patents

Inhibidores de cinesina como producto terapeuticos para el cancer

Info

Publication number
CO6290651A2
CO6290651A2 CO10070369A CO10070369A CO6290651A2 CO 6290651 A2 CO6290651 A2 CO 6290651A2 CO 10070369 A CO10070369 A CO 10070369A CO 10070369 A CO10070369 A CO 10070369A CO 6290651 A2 CO6290651 A2 CO 6290651A2
Authority
CO
Colombia
Prior art keywords
compounds
inhibitors
cancers
novel
cinesine
Prior art date
Application number
CO10070369A
Other languages
English (en)
Inventor
Tinya Abrams
Paul A Barsanti
David Duhl
Michel Faure
Paul A Renhowe
Annette Walter
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40328566&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6290651(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CO6290651A2 publication Critical patent/CO6290651A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/61—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms not forming part of a nitro radical, attached to ring nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención proporciona novedosos compuestos de imidazol que inhiben la actividad de la proteína de huso de cinesina (KSP, también denominada como Eg5). Los inhibidores de KSP pueden reducir la proliferación celular indeseada, y proporcionan otros efectos terapéuticos. La invención también proporciona composiciones farmacéuticas que contienen estos compuestos novedosos, y métodos para utilizar los inhibidores de KSP novedosos y sus composiciones farmacéuticas para tratar diferentes tipos de cánceres. Los compuestos, composiciones y métodos de la invención son en especial útiles para el tratamiento de ciertas clases de cánceres que son resistentes a los tratamientos con fármacos convencionales, debido a que se muestra que estos cánceres siguen siendo sensibles a los compuestos de la invención.
CO10070369A 2007-12-14 2010-06-10 Inhibidores de cinesina como producto terapeuticos para el cancer CO6290651A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1396607P 2007-12-14 2007-12-14

Publications (1)

Publication Number Publication Date
CO6290651A2 true CO6290651A2 (es) 2011-06-20

Family

ID=40328566

Family Applications (1)

Application Number Title Priority Date Filing Date
CO10070369A CO6290651A2 (es) 2007-12-14 2010-06-10 Inhibidores de cinesina como producto terapeuticos para el cancer

Country Status (30)

Country Link
US (2) US8252832B2 (es)
EP (1) EP2229170B1 (es)
JP (1) JP5501976B2 (es)
KR (1) KR20100098394A (es)
CN (1) CN101939005B (es)
AR (1) AR069676A1 (es)
AU (1) AU2008337570B2 (es)
BR (1) BRPI0821248A2 (es)
CA (1) CA2708822A1 (es)
CL (1) CL2008003707A1 (es)
CO (1) CO6290651A2 (es)
CR (1) CR11412A (es)
DO (1) DOP2010000175A (es)
EA (1) EA018014B1 (es)
EC (1) ECSP10010248A (es)
ES (1) ES2459442T3 (es)
GE (1) GEP20125647B (es)
GT (1) GT201000172A (es)
IL (1) IL205831A0 (es)
MA (1) MA31872B1 (es)
MY (1) MY150214A (es)
NI (1) NI201000091A (es)
NZ (1) NZ585142A (es)
PA (1) PA8807801A1 (es)
PE (1) PE20091451A1 (es)
SM (1) SMP201000095B (es)
TN (1) TN2010000204A1 (es)
TW (1) TW200930704A (es)
UY (1) UY31532A1 (es)
WO (1) WO2009077448A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8765817B1 (en) 2008-12-03 2014-07-01 Arrowhead Center, Inc. Selective inhibitors of EG5 motors and methods of use
US8349899B1 (en) 2008-12-03 2013-01-08 Arrowhead Center, Inc. Selective inhibitors of EG5 motors and methods of use
CN103153970A (zh) * 2010-04-15 2013-06-12 诺瓦提斯公司 作为ksp抑制剂的*唑和噻唑化合物
US9498540B2 (en) 2013-03-15 2016-11-22 Novartis Ag Cell proliferation inhibitors and conjugates thereof
CN105451773A (zh) * 2013-03-15 2016-03-30 诺华股份有限公司 细胞增殖抑制剂及其缀合物
WO2016020791A1 (en) 2014-08-05 2016-02-11 Novartis Ag Ckit antibody drug conjugates
BR112017027813A2 (pt) * 2015-06-22 2018-08-28 Bayer Pharma Aktiengesellschaft conjugados de agente de ligação-droga (adcs) e conjugados de agente de ligação-pró-droga (apdcs) tendo grupos enzimaticamente cliváveis
CN105418527A (zh) * 2015-12-28 2016-03-23 青岛友诚高新技术有限公司 一种具有抗乳腺导管癌活性的化合物及其制备方法、用途
CN105646361B (zh) * 2016-02-17 2017-12-01 吉首大学 一种2,4,5‑三芳基咪唑型化合物及其制法和用途
AU2017380871A1 (en) 2016-12-21 2019-07-11 Bayer Aktiengesellschaft Antibody drug conjugates (ADCs) having enzymatically cleavable groups
CN106668863B (zh) * 2017-02-21 2019-04-23 南方医科大学 靶向ktn1治疗皮肤鳞状细胞癌的药物
GB201706162D0 (en) * 2017-04-19 2017-05-31 Nat Univ Singapore Compounds
CN111954532A (zh) * 2018-04-13 2020-11-17 上海交通大学医学院附属瑞金医院 杂芳基酰胺类化合物的抗肿瘤多药耐药性、治疗癌症的用途和蛋白质-药物分子复合物
CN109646679A (zh) * 2019-01-28 2019-04-19 中国科学院长春应用化学研究所 铁离子螯合剂及其可药用盐的用途
CN111529526B (zh) * 2020-04-14 2021-04-23 广州领晟医疗科技有限公司 一种化合物在制备治疗急性胰腺炎的药物中的用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06014909A (es) * 2004-06-18 2007-02-28 Chiron Corp Derivados de n-(1-(1-bencil -4-fenil-1h -imidazol -2-il)-2, 2-dimetilpropil) benzamida y compuestos relacionados como inhibidores de proteina de huso de cinesina (ksp) para el tratamiento del cancer.
US7271271B2 (en) 2004-06-28 2007-09-18 Amgen Sf, Llc Imidazolo-related compounds, compositions and methods for their use
TW200800951A (en) 2005-08-09 2008-01-01 Novartis Ag Substituted imidazole compounds as KSP inhibitors
JP2010515687A (ja) 2007-01-05 2010-05-13 ノバルティス アーゲー キネシンスピンドルタンパク質阻害剤（ｅｇ−５）としてのイミダゾール誘導体

Also Published As

Publication number Publication date
NI201000091A (es) 2011-03-15
SMAP201000095A (it) 2010-09-10
AU2008337570A1 (en) 2009-06-25
US8252832B2 (en) 2012-08-28
CN101939005A (zh) 2011-01-05
US20130012560A1 (en) 2013-01-10
PE20091451A1 (es) 2009-10-19
AR069676A1 (es) 2010-02-10
SMP201000095B (it) 2011-09-09
US20090239922A1 (en) 2009-09-24
GT201000172A (es) 2012-04-30
TW200930704A (en) 2009-07-16
US8664256B2 (en) 2014-03-04
IL205831A0 (en) 2010-11-30
DOP2010000175A (es) 2010-06-30
BRPI0821248A2 (pt) 2015-06-16
ES2459442T3 (es) 2014-05-09
CL2008003707A1 (es) 2009-06-05
CR11412A (es) 2010-06-30
UY31532A1 (es) 2009-08-03
ECSP10010248A (es) 2010-07-30
PA8807801A1 (es) 2009-07-23
EA201000900A1 (ru) 2011-02-28
GEP20125647B (en) 2012-09-25
JP5501976B2 (ja) 2014-05-28
TN2010000204A1 (en) 2011-11-11
EA018014B1 (ru) 2013-04-30
WO2009077448A1 (en) 2009-06-25
MA31872B1 (fr) 2010-11-01
MY150214A (en) 2013-12-13
EP2229170B1 (en) 2014-01-22
AU2008337570B2 (en) 2012-04-05
EP2229170A1 (en) 2010-09-22
JP2011506402A (ja) 2011-03-03
KR20100098394A (ko) 2010-09-06
CA2708822A1 (en) 2009-06-25
NZ585142A (en) 2012-03-30
CN101939005B (zh) 2015-12-16

Similar Documents

Publication Publication Date Title
CO6290651A2 (es) Inhibidores de cinesina como producto terapeuticos para el cancer
CL2023002090A1 (es) Inhibidores de kras tricíclicos fusionados
MX2020008559A (es) Compuestos heterocíclicos como inhibidores de la quinasa.
PE20181803A1 (es) Inhibidores de mcl-1 macrociclicos para tratar el cancer
DOP2003000614A (es) Derivados de bencimidazol n3 alquilado como inhibidores de mek (n3 alkylated benzimidazole
DOP2011000110A (es) “derivados de bencimidazol n3 alquilados como inhibidores de mek”
GT200800202A (es) Quinazolinas para la inhibicion de pdk1
CO6361927A2 (es) Quinazolinas para inhibicion de pdk1
CU20080027A7 (es) Bencimidazoles sustituidos como inhibidores de cinasa
ECSP088536A (es) DERIVADOS DE PIRIDO-, PIRAZO- Y PIRIMIDO-PIRIMIDINA COMO INHIBIDORES DE mTOR
NO20090581L (no) Hydroksylerte og metoksylerte syklopenta[D]pyrimidiner som AKT-proteinkinaseinhibitorer
EA201591932A1 (ru) ПРИМЕНЕНИЕ ЗАМЕЩЕННЫХ 2,3-ДИГИДРОИМИДАЗО[1,2-c]ХИНАЗОЛИНОВ ДЛЯ ЛЕЧЕНИЯ ЛИМФОМ
CR20230057A (es) Compuestos tríciclicos de urea como inhibidores de jak2 v617f
CR10188A (es) Antagonistas de receptor de factor de crecimiento de tipo insulina (igf-ir) como auxiliares para tratamiento de cancer de prostata
DK2054418T3 (da) Dihydrothieno-pyrimidiner som AKT-proteinkinase-inhibitorer
CO2024001285A2 (es) Compuestos tricíclicos como inhibidores de kras
ECSP22098041A (es) Inhibidores alostéricos de egfr y métodos de uso de estos
CL2022002148A1 (es) Inhibidores heterocíclicos de pad4
BR112021025445A2 (pt) Composto, composição farmacêutica, uso de um composto e método para o tratamento ou profilaxia de câncer e para o tratamento ou profilaxia de câncer de pulmão de células não pequenas
CU20100121A7 (es) Inhibidores de cinesina como productos terapéuticos para el cáncer
BR112023000654A2 (pt) Composto de pirazolopirimidina usado como inibidor de atr quinase
AR126389A1 (es) Compuestos tricíclicos como inhibidores de kras
CO2022017969A2 (es) Compuestos de imidazopiridazina con actividad como inhibidores de alk2
CL2022000217A1 (es) Inhibidores de enzimas
CL2023000837A1 (es) Derivados de tetrazol como inhibidores de trpa1

Legal Events

Date Code Title Description
FG Application granted
FD Application lapsed